 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Benitec Australia Ltd
|
-
Benitec secures further rights to HIV Therapeutic
(30 Apr 2008)
Collaboration with City of Hope in HIV trial
Benitec Limited has secured further intellectual property rights that underpin its HIV/AIDS lymphoma therapeutic currently undergoing clinical trials at City of Hope in Duarte, California. The therapeutic uses RNAi technology covered by Benitec's ...
-
Benitec appoints new CFO
(27 Sep 2006)
The Board of Directors of Benitec Limited announced that the Company had appointed Paul McMahon as the new Chief Financial Officer (CFO) effective immediately.Paul is a CPA and Chartered Secretary who brings extensive financial management experience ...
-
Sigma-Aldrich Initiates RNAi Partnership Program
(26 Apr 2006)
Sigma-Aldrich has announced the establishment of a worldwide RNAi Partnership Program with select academic institutions to advance functional genomics research. Scientists from participating organizations will benefit from unique access to a broad ...
-
Benitec delays IND filing for HIV/AIDS therapeutic pending resolution of manufacturing result
(09 Feb 2006)
Benitec Ltd. announced that the Investigational New Drug (IND) filing with the US Food & Drug Administration (FDA) for its HIV/AIDS therapeutic will be delayed. The delay is due to one aberrant result in the release tests of the clinical materials, ...
-
Benitec grants Sigma-Aldrich license to RNAi patent portfolio
(27 Oct 2005)
Sigma-Aldrich Acquires Equity Stake in Benitec
Benitec Ltd. and Sigma-Aldrich Corporation announced the signing of two major agreements, one in which Sigma acquires an equity stake in Benitec and one in which Benitec grants Sigma a license for the use of Benitec's RNAi technology. Benitec will ...
-
Alnylam and Benitec Form Alliance on Fundamental Intellectual Property for RNAi Therapeutics
(14 Apr 2005)
Alnylam Pharmaceuticals, Inc. and Benitec Ltd. announced a licensing agreement covering fundamental intellectual property (IP) in the field of RNA interference (RNAi). Under the agreement, Alnylam will provide Benitec and its licensees an option to ...
-
Promega seeks to stop unlawful Benitec licensing activities of ddRNAi technology
(12 Nov 2004)
To protect its exclusive licensing rights, Promega filed a motion to stop Benitec from further licensing activities of ddRNAi technology in the areas which have been granted exclusively to Promega. Filing with the United States District Court for ...
-
Benitec Obtains License to Unique RNAi Non-Viral Delivery Technology from Stanford University
(18 Oct 2004)
Benitec is pleased to announce an exclusive licensing deal with Stanford University. Under the license, Benitec receives exclusive rights to use the Minicircle DNA technology pioneered at Stanford University for all RNAi therapeutic uses, with ...
-
Benitec Announces First ddRNAi Therapeutic License With Revivicor & the Allowance of its Canadian Patent
(11 Oct 2004)
Benitec is pleased to announce the granting of its first therapeutic license to Revivicor, Inc (Virginia, USA). Benitec's ddRNAi technology will be used in Revivicor's pioneering work in the field of regenerative medicine; being the replacement of ...
-
Benitec Initiates Patent Infringement Lawsuit
(29 Mar 2004)
Queensland. Benitec Ltd announced that it initiated patent infringement lawsuits in the United States District Court for the District of Delaware against Nucleonics, Inc., Ambion, Inc., and Genscript Corporation to protect its gene silencing ...
|
|
|
|
|
Top
